INTRODUCTION
============

Anemia is a common complication in patients with chronic kidney disease (CKD) who receive maintenance hemodialysis (HD) \[[@sfy014-B1], [@sfy014-B2]\]. The standard of care for treating this anemia uses recombinant human erythropoietin (rhEPO) and its analogs, supplemented with intravenous (IV) iron administration \[[@sfy014-B3]\]. Well-controlled clinical outcomes trials have demonstrated that rhEPO and its analogs increase the risk of cardiovascular events, stroke and death when targeting higher hemoglobin levels (\>13 g/dL) \[[@sfy014-B4]\]. These findings led the US Food and Drug Administration to modify safety language in labeling for rhEPO and its analogs in 2007 and 2011 to limit their initiation in HD patients until the hemoglobin level is \<10 g/dL and to reduce or interrupt treatment if the hemoglobin level approaches or exceeds 11 g/dL \[[@sfy014-B8], [@sfy014-B9]\].

Given the safety concerns with rhEPO and its analogs, hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (PHIs) including daprodustat (previously GSK1278863) are being developed to treat anemia of CKD \[[@sfy014-B10]\]. These agents stimulate erythropoiesis by inhibiting the HIF-prolyl hydroxylase (PHD) enzymes PHD1, PHD2 and PHD3. This leads to stabilization of HIF-α transcription factors and induction of HIF-responsive genes involved in adaptation to hypoxia---including erythropoietin (EPO), vascular endothelial growth factor (VEGF) and genes that regulate iron uptake, mobilization and transport---resulting in decreased hepcidin production \[[@sfy014-B15], [@sfy014-B16]\]. Potential advantages of HIF-PHI agents over rhEPO and its analogs, which are being tested in long-term studies, include increasing hemoglobin without exposing the patient to the supraphysiologic EPO levels associated with rhEPO and its analogs, improving iron availability for erythropoiesis and correction of anemia in patients who do not respond to rhEPO and its analogs and treating anemia without producing hypertension. It is postulated, for these reasons, that daprodustat may be associated with fewer cardiovascular events than rhEPO and its analogs.

A previous 4-week study with daprodustat demonstrated its ability to maintain hemoglobin levels in HD patients who switched from rhEPO \[[@sfy014-B13]\]. The effects of daprodustat on hemoglobin were achieved with small increases in circulating EPO levels that averaged 17-fold lower than in the rhEPO control group \[[@sfy014-B17]\]. We report the results of a trial designed to further evaluate the dose--response relationship between daprodustat and hemoglobin levels over the first 4 weeks of treatment (primary endpoint) and to evaluate the safety and efficacy of daprodustat over 24 weeks in achieving and maintaining hemoglobin levels within a prespecified target range (10--11.5 g/dL) in HD participants switched to daprodustat from a stable dose of rhEPO.

MATERIALS AND METHODS
=====================

Study population
----------------

Informed consent was obtained from all participants. Eligible participants were on adequate HD three to five times weekly, on stable rhEPO doses for 8 weeks before randomization and had stable hemoglobin levels between 9 and 11.5 g/dL based on the average of three values obtained during the screening phase. Maintenance oral or IV iron supplementation was allowed, but participants were excluded if ferritin was \<100 ng/mL and/or transferrin saturation (TSAT) was \<12% or \>57%. The complete inclusion, exclusion and study medication stopping criteria and prohibited drugs can be found in the [Supplementary data, Item S1](#sup1){ref-type="supplementary-material"}, and the iron protocol is shown in [Supplementary data, Table S1](#sup1){ref-type="supplementary-material"} in Item S2.

Study design
------------

This global study (ClinicalTrials.gov identifier NCT01977482; EudraCT number 2013-002682-19) was conducted from 15 November 2013 to 18 March 2015 at 107 sites in 16 countries (67 sites in 15 countries randomized participants), performed in adherence with the Declaration of Helsinki and approved by relevant institutional review boards or ethics committees. The investigators or study site staff were responsible for detecting, documenting and reporting adverse events (AEs). An internal GlaxoSmithKline Safety Review Team reviewed blinded safety data in stream and an independent data monitoring committee periodically reviewed the same safety data but unblinded.

The study consisted of a 4-week screening phase, 24-week treatment phase and a follow-up visit ∼4 weeks after completing treatment. Participants who discontinued study medication or withdrew early from the study attended an early withdrawal (EW) visit, a follow-up visit after 4 weeks, phone assessments aligned with the remaining key study visits as required and an EW final visit at Week 24. Study investigators or staff were responsible for monitoring and recording AEs. AEs were collected from the start of study treatment and until the follow-up contact. (Additional information regarding the study design is included in the [Supplementary data, Item S3 and Figure S1](#sup1){ref-type="supplementary-material"}.) Eligible participants were stratified by region (Japan versus non-Japan) and prior rhEPO dose and then randomized 2:2:2:2:1:2 to receive blinded daprodustat tablets once daily at starting doses of 4, 6, 8, 10 or 12 mg or placebo tablets (control group).

At Week 4, the daprodustat and control groups were to have doses adjusted in order to achieve and maintain hemoglobin within the prespecified target range (10--11.5 g/dL). Participants randomized to daprodustat had automatic dose adjustments through an interactive voice/web response system based on a prespecified dose-adjustment algorithm, with the dose of daprodustat continually being blinded. Control participants received open-label rhEPO (epoetins or their biosimilars, or darbepoetin), with the rhEPO type, dose and route of administration being determined by the investigator. Study medications were permanently discontinued if hemoglobin levels were \<7.5 g/dL, and participants were managed per standard of care (e.g. rhEPO and its analogs and/or iron). (A complete description of the primary and secondary endpoints and associated study assessments are listed in [Table 1](#sfy014-T1){ref-type="table"}.) Details of the study assessments performed, including laboratory assessments, AE reporting, echocardiology and ophthalmology exams, are listed in [Supplementary data, Item S4](#sup1){ref-type="supplementary-material"}. Table 1.Study objectives and endpointsObjectivesEndpointsPrimaryCharacterize the dose--response relationship between daprodustat and hemoglobin at Week 4Hemoglobin change from baseline at Week 4SecondaryCharacterize the ability of daprodustat to achieve hemoglobin within the target range (10.0--11.5 g/dL)Hemoglobin concentration at Week 24Percentage of time within, below and above target range between Weeks 20 and 24Number (%) of participants with hemoglobin in the target range at Week 24Number (%) of participants reaching predefined hemoglobin stopping criteriaCharacterize the effect of daprodustat on measures of iron metabolism and utilization, on indices of hematopoiesis and EPO and on VEGFChange from baseline in hepcidin, ferritin, transferrin, TSAT, total iron, TIBC and CHr at Week 24Change from baseline in hematocrit, RBCs and reticulocyte number at Week 24Maximum observed change from baseline in EPOMaximum observed change from baseline in VEGFSafetyAssess the safety and tolerability of daprodustat following QD administration for 24 weeksIncidence and severity of AEs and SAEsReasons for discontinuation of study medicationDiscontinuation for safety-related reasons, e.g. prespecified stopping criteria or AEAbsolute values and changes from baseline in laboratory parameters, sPAP, LVEF, ophthalmology assessments and vital signsPreliminary assessment of MACE and other CV events[^1]

Statistical analyses
--------------------

Analyses were performed on the intent-to-treat (ITT) population. All analyses were estimation based; no formal hypothesis testing was planned. Results are expressed using descriptive statistics.

For the primary analysis, a Bayesian approach was used to characterize the relationship between daprodustat dose and hemoglobin using an E~max~ model (details are described in the [Supplementary data, Item S5](#sup1){ref-type="supplementary-material"}). For the secondary analysis, time (days) spent with hemoglobin within the target range while on treatment between Weeks 20 and 24 was calculated using the method of Rosendaal *et al.* \[[@sfy014-B18]\] and percentage of time within, above, and below hemoglobin target range between Weeks 20 and 24 was reported. The number of participants within, above and below the hemoglobin target range was determined at Week 24. Safety data were summarized by treatment group. This study was designed as a dose-ranging study and, as such, was not designed to make any formal comparisons between the daprodustat and control arms.

The sample size for daprodustat was sufficient to estimate the dose--response relationship and to provide data on at least 100 participants exposed to daprodustat for 24 weeks (see [Supplementary data, Item S5](#sup1){ref-type="supplementary-material"} for complete justification).

RESULTS
=======

Participant disposition and baseline characteristics
----------------------------------------------------

The study included 177 participants randomized to one of the daprodustat dose groups and 39 participants randomized to the control group. Of those randomized, all were included in the safety population and 171 (97%) in the ITT population. The overall study completion rate was 87%, with 85% of participants in the daprodustat and 92% in the control groups completing the study, i.e. the participant completed all study visits or the abbreviated schedule if study medication was discontinued ([Figure 1](#sfy014-F1){ref-type="fig"}). The predominant reason in both groups for participants not completing the study was withdrawal by the participant (withdrew consent): 8% in the combined daprodustat group and 5% in the control group. For those randomized to daprodustat, the highest rates of noncompleters were in groups with a starting dose of daprodustat of 4 or 12 mg.

![Study flow diagram.^a^Completed all study visits or abbreviated schedule if study medication was discontinued. ^b^Twenty-two participants discontinued study medication because of AEs; however, 12 of these participants had AEs that were actually protocol-defined stopping criteria and are presented here in the stopping criteria category rather than the AE category. Protocol-defined stopping criteria are detailed in the [Supplementary data, Item S1](#sup1){ref-type="supplementary-material"}. IP, investigational product; PI, principal investigator.](sfy014f1){#sfy014-F1}

Baseline and demographic characteristics are shown for the daprodustat and control groups ([Table 2](#sfy014-T2){ref-type="table"}). In the ITT population, mean age (57.9 and 61.6 years), percentage of males (65% and 60%), mean weight (80.3 and 84.8 kg) and mean body mass index (28.2 and 30.1 kg/m^2^) were well balanced in the combined daprodustat and control groups, respectively. Table 2.**Baseline and demographic characteristics (ITT population and safety population where indicated**)Combined daprodustatControl(*n* = 171)(*n* = 39)Age[^a^](#tblfn2){ref-type="table-fn"}, years *n*17139 mean (SD)59.6 (13.3)59.7 (18.7)Sex[^a^](#tblfn2){ref-type="table-fn"} *n*17139 male, *n* (%)108 (63)26 (67)Weight[^a^](#tblfn2){ref-type="table-fn"} (kg) *n*17139 mean (SD)77.8 (23.0)76.3 (19.8)BMI[^a^](#tblfn2){ref-type="table-fn"} (kg/m^2^) *n*17039 mean (SD)27.7 (7.5)27.2 (5.8)Race[^a^](#tblfn2){ref-type="table-fn"}, *n* (%) *n*17139 White124 (73)23 (59) African American18 (11)7 (18) Asian27 (16)7 (18) Other2 (1)2 (5)Geographical region[^a^](#tblfn2){ref-type="table-fn"}, *n* (%) *n*17139 Japan19 (11)5 (13) North America44 (26)13 (33) Russia37 (22)9 (23) Rest of the world71 (42)12 (31)Mode of dialysis[^b^](#tblfn3){ref-type="table-fn"}, *n* (%) *n*17739 Hemodiafiltration51 (29)5 (13) HD120 (68)33 (85) Hemofiltration6 (3)2 (5)Prior rhEPO dose stratification[^a^](#tblfn2){ref-type="table-fn"}^,^[^c^](#tblfn4){ref-type="table-fn"}, *n* (%) *n*17139 Low rhEPO dose143 (84)33 (85) High rhEPO dose28 (16)6 (15)Baseline hemoglobin level[^a^](#tblfn2){ref-type="table-fn"} (g/dL) *n*17139 mean (SD)10.4 (0.66)10.6 (0.94)CV risk factors[^b^](#tblfn3){ref-type="table-fn"}, *n* (%) *n*17739 Any CV risk factor166 (94)38 (97) Hypertension160 (90)37 (95) Hyperlipidemia85 (48)20 (51) Diabetes mellitus62 (35)18 (46) Angina pectoris13 (7)2 (5)[^2][^3][^4][^5]

Hemoglobin dose--response
-------------------------

At baseline, mean hemoglobin across the daprodustat and control groups was 10.4 g/dL (individual group means ranged from 10.3 to 10.6 g/dL). Over the 4-week fixed-dose treatment phase, daprodustat doses up to 10 mg once daily produced a dose-dependent change in hemoglobin from baseline (12 mg produced similar responses to 10 mg), with changes evident at Week 2; hemoglobin decreased in the control group receiving placebo ([Figure 2](#sfy014-F2){ref-type="fig"}, [Supplementary data, Table S2, Item S6](#sup1){ref-type="supplementary-material"}).

![Mean change in hemoglobin levels from baseline to Week 4 by treatment group \[intent-to-treat (ITT) population\].](sfy014f2){#sfy014-F2}

The dose--response model-based analysis estimated that a dose of 4.4 mg of daprodustat would produce a 0 mg/dL change in hemoglobin over 4 weeks after switching from rhEPO and that a dose of 0.42 mg would be the minimally effective dose (i.e. −0.5 g/dL change from baseline). (Additional outputs of the model are provided in the [Supplementary data, Item S6](#sup1){ref-type="supplementary-material"}.)

Change in hemoglobin levels over time
-------------------------------------

After the fixed-dosing phase, when doses were titrated to achieve the hemoglobin target range (10--11.5 g/dL), hemoglobin levels for those receiving daprodustat (combining all starting doses) converged toward the hemoglobin target. In the control group, hemoglobin levels returned to baseline by Week 14 after restarting rhEPO at Week 4 ([Figure 3](#sfy014-F3){ref-type="fig"}).

![Mean hemoglobin levels over 24 weeks by combined daprodustat groups versus controls \[intent-to-treat (ITT) population\]. BL, baseline.](sfy014f3){#sfy014-F3}

At Week 24, the mean ± standard deviation (SD) hemoglobin change from baseline was 0.03 ± 1.05 g/dL for the daprodustat group and −0.11 ± 1.43 g/dL for the control group, with 58% of participants in each group having hemoglobin values within the target range. The median percentage of time within the hemoglobin target range over the last 4 study weeks was 60% for the daprodustat group and 66% for the control group. A sensitivity analysis of the percentage of time within, above and below the hemoglobin target range between Weeks 20 and 24 is shown in [Supplementary data, Table S3, Item S6](#sup1){ref-type="supplementary-material"}. The median final dose of daprodustat was 6 mg and the median final rhEPO dose, standardized to IV epoetin, was 55.8 U/kg/week.

Two (1%) participants in the combined daprodustat group met protocol-defined hemoglobin stopping criteria (\<7.5 g/dL). Hemoglobin levels ≥13 g/dL were observed in 17 (10%) participants in the combined daprodustat group, with 82% occurring in those randomized to starting doses ≥8 mg. Hemoglobin levels ≥13 g/dL were observed in one (3%) participant in the control group. Few participants in either group received red blood cell (RBC) transfusions during the study \[7 (4%) combined daprodustat; 2 (5%) control\], with acute bleeding being the most common reason.

The changes in hemoglobin were associated with expected changes in hematocrit, RBC count and absolute reticulocyte count ([Supplementary data, Table S4, Item S7](#sup1){ref-type="supplementary-material"}).

Erythropoietin and VEGF levels
------------------------------

Baseline plasma EPO levels were similar across the daprodustat and control groups. The median maximum observed EPO level was 36.5 IU/L for the combined daprodustat group and 522.9 IU/L for the control group ([Table 3](#sfy014-T3){ref-type="table"}). Table 3.Levels and change from baseline for EPO and VEGF (ITT population)Combined daprodustatControl(*n* = 171)(*n* = 39)EPO levels (IU/L)Baseline[^a^](#tblfn6){ref-type="table-fn"} *n*16336 Median (minimum, maximum)9.2 (2.5, 755.8)9.3 (2.6, 54.6) Maximum observed EPO level[^b^](#tblfn7){ref-type="table-fn"}, median (minimum, maximum)36.5 (5.2, 1379.3)522.9 (19.0, 51 200.0) Maximum observed CFB in EPO level[^b^](#tblfn7){ref-type="table-fn"}, median (minimum, maximum)27.1 (−724.5, 1371.6)512.9 (5.3, 51 195.4)VEGF levels (ng/L)Baseline[^a^](#tblfn6){ref-type="table-fn"} *n*16336 Median (minimum, maximum)186.9 (64.3, 1142.6)220.0 (78.2, 595.7) Maximum observed VEGF[^b^](#tblfn7){ref-type="table-fn"} median (minimum, maximum)270.0 (81.8, 808.3)269.4 (98.7, 924.0)[^6][^7][^8]

Across the treatment and control groups, plasma VEGF levels were similar at baseline ([Table 3](#sfy014-T3){ref-type="table"}). VEGF levels were highly variable at all time points, with no clear signal for a change in any treatment group ([Table 3](#sfy014-T3){ref-type="table"}).

Measures of iron metabolism and IV iron use
-------------------------------------------

Mean baseline levels in hepcidin and other iron parameters were similar across the treatment and control groups ([Table 4](#sfy014-T4){ref-type="table"}). Hepcidin levels decreased for participants in the daprodustat group over the first 4 weeks and remained below baseline for the combined daprodustat group throughout the treatment phase ([Figure 4](#sfy014-F4){ref-type="fig"}, [Table 4](#sfy014-T4){ref-type="table"}). Participants in the control group had an initial increase in hepcidin while on placebo, and once rhEPO was restarted at Week 4, mean hepcidin levels decreased over time and approached baseline by the end of treatment. (Results for other iron parameters are provided in [Table 4](#sfy014-T4){ref-type="table"} and [Supplementary data, Figure S2, Item S8](#sup1){ref-type="supplementary-material"}.) Table 4.Changes from baseline for markers of iron metabolism (ITT population)Combined daprodustat (*n* = 171)Control (*n* = 39)Baseline% CFB at Week 24Baseline% CFB at Week 24Hepcidin (µg/L) *n*1711143832 Geometric mean388.2--20.6334.43.6 95% CI352.9, 427.1--29.9, --10.0274.7, 407.1--20.4, 34.9TSAT (%) *n*1711153932 Geometric mean29.6--4.430.7--9.0 95% CI27.9, 31.5--11.2, 2.827.0, 35.0--27.3, 13.9BaselineCFB at Week 24BaselineCFB at Week 24Ferritin (µg/L) *n*1711153933 Mean585.1−59.9459.056.8 SD429.7331.8261.0214.3TIBC (µmol/L) *n*1711153932 Mean41.65.541.2−2.0 SD6.66.67.24.5Total iron (µmol/L) *n*1711153933 Mean13.40.913.4−0.8 SD6.16.14.97.6[^9]

![Mean hepcidin levels over 24 weeks by combined daprodustat groups versus controls \[intent-to-treat (ITT) population\].](sfy014f4){#sfy014-F4}

Approximately 67% of participants in both the treatment and control groups were receiving IV iron at baseline. During the treatment phase, the median IV iron dose, adjusted by exposure, was similar (44.1 versus 42.7 mg/week) for the daprodustat and control groups, respectively.

Safety
------

The overall incidence of any AEs through the 24-week treatment phase was similar in the combined daprodustat and control groups ([Table 5](#sfy014-T5){ref-type="table"}). Of the AEs most frequently reported, diarrhea, nausea, hypertension and hyperkalemia were reported more often in the combined daprodustat group, while nasopharyngitis and back pain were reported more often in the control group. While hyperkalemia was reported as an AE more frequently in the daprodustat group than in the control group ([Table 5](#sfy014-T5){ref-type="table"}), the proportion of hyperkalemia events of potential clinical importance (potassium \>6.3 mmol/L) was slightly higher in the control group (17%) than in the daprodustat group (14%). Table 5.AEs and frequency of MACE and component end points in the combined daprodustat and control groups (safety population)Combined daprodustatControl(*n *= 177)(*n* = 39)AEs occurring in ≥5% of participantsAny event, *n* (%)129 (73)31 (79) Diarrhea16 (9)2 (5) Nasopharyngitis15 (8)5 (13) Nausea13 (7)0 Headache9 (5)2 (5) Hypertension9 (5)1 (3) Hyperkalemia8 (5)0 Back pain7 (4)4 (10)MACE composite endpoints[^a^](#tblfn10){ref-type="table-fn"}, *n* (%) Any MACE[^b^](#tblfn11){ref-type="table-fn"}7 (4)0 Any MACE+[^c^](#tblfn12){ref-type="table-fn"}10 (6)1 (3)Components of composite endpoints[^d^](#tblfn13){ref-type="table-fn"}, *n* (%) All-cause mortality5 (3)0 MI (fatal or nonfatal)3 (2)0 Stroke (fatal or nonfatal)00 Hospitalization due to heart failure5 (3)1 (3)[^10][^11][^12][^13][^14]

Serious AEs (SAEs) were reported in 31 (18%) participants in the combined daprodustat group and in 10 (26%) participants in the control group. The most common SAEs in the combined daprodustat group were acute myocardial infarction (MI) and cardiac arrest, in three participants each, followed by unstable angina, cardiac failure, hypertensive crisis, lobar pneumonia and pulmonary edema in two participants each. All other SAEs were reported in one participant each. In the control group, no specific SAE was reported in more than one participant. A summary of cardiovascular events, including major adverse cardiovascular events (MACEs) and component endpoints, are summarized in [Table 5](#sfy014-T5){ref-type="table"}. Other preidentified AEs of interest are described in the [Supplementary data, Item S9](#sup1){ref-type="supplementary-material"}.

Mean baseline and absolute changes in left ventricular ejection fraction and estimated systolic pulmonary artery pressure (sPAP) were similar for the daprodustat and control groups ([Supplementary data, Table S5, Item S9](#sup1){ref-type="supplementary-material"}). An increase of \>20 mmHg from baseline in estimated sPAP was observed in eight (7%) participants in the combined daprodustat group and in no participants in the control group.

Mean changes from baseline in blood pressure (BP) for the combined daprodustat and control groups are presented in [Table 6](#sfy014-T6){ref-type="table"}. Although the mean change from baseline in systolic BP was greater in the control group than the combined daprodustat group by ∼5 mmHg, more participants in the combined daprodustat group \[22 (12%)\] had an increase in the number of antihypertensive medications relative to the control group \[2 (5%)\]. Table 6.Summary of SBP and DBP at Week 24 (ITT population)Combined daprodustatControl*(n* = 171)(*n* = 39)SBP (mmHg) Baseline[^a^](#tblfn15){ref-type="table-fn"}  *n*16336  Mean (SD)141.5 (17.4)139.5 (18.7) Change from baseline at Week 24  *n*11231  Mean (SD)0.7 (18.0)5.6 (19.3)DBP (mmHg) Baseline[^a^](#tblfn15){ref-type="table-fn"}  *n*16336  Mean (SD)74.9 (12.6)75.5 (11.9) Change from baseline at Week 24  *n*11231  Mean (SD)0.3 (9.7)1.3 (11.5)[^15][^16]

No adverse trends were noted for clinical laboratory values and electrocardiogram parameters. Furthermore, no changes were seen in visual acuity or intraocular pressure based on the protocol-specified ophthalmology exams (data not shown).

DISCUSSION
==========

This study is the largest and longest completed to date in the HD population switched from rhEPO to treatment with the HIF-PHI, daprodustat. Over the first 4 weeks, daprodustat produced dose-dependent changes in hemoglobin up to the 10-mg dose, with dose separation noted as early as the first assessment at 2 weeks. These increases in hemoglobin were associated with the expected increase in absolute reticulocyte count, thus supporting increased erythropoiesis as the main driver for daprodustat's effect on hemoglobin.

Over the 24-week treatment phase, daprodustat maintained hemoglobin levels, with 2 (1%) participants requiring permanent discontinuation of study medication (hemoglobin \<7.5 g/dL). Although 17 (10%) participants on daprodustat required a dose interruption for hemoglobin ≥13 g/dL, this was influenced by the random starting dose allocation, as most excursions occurred with starting doses ≥8 mg. The proportion of participants on daprodustat who were within the hemoglobin target range (58%) at Week 24 is lower than that observed in a recently conducted 24-week study in participants with CKD and could be due to participants in this study being assigned to random starting doses (2--12 mg). In the CKD study, starting doses were assigned based on salient baseline parameters (74% in the target range at Week 24; \[[@sfy014-B31]\]).

In the daprodustat group, hemoglobin was maintained with postdose plasma EPO levels similar to those observed during acclimatization to high altitude \[[@sfy014-B19]\]. In contrast, maximum observed postdose EPO levels in the control group were 14-fold higher than in the daprodustat group, a finding consistent with prior daprodustat clinical studies \[[@sfy014-B13]\]. If higher EPO levels contribute to the cardiovascular risk associated with rhEPO \[[@sfy014-B20]\], then daprodustat may provide a safer cardiovascular risk profile.

Consistent with findings from prior trials with daprodustat and vadadustat \[[@sfy014-B13], [@sfy014-B14], [@sfy014-B21]\], in this 24-week study, daprodustat, as well as the control, had minimal if any effect on VEGF, a known target gene of HIF \[[@sfy014-B22]\]. This is consistent with preclinical work demonstrating that VEGF expression is less sensitive to HIF activation than is EPO expression (GlaxoSmithKline, unpublished data) \[[@sfy014-B25]\].

Participants were iron replete at baseline and an iron protocol provided thresholds for IV iron use to ensure participants remained replete. Decreases in hepcidin, ferritin and TSAT and increases in total iron-binding capacity (TIBC) during the initial 4-week, fixed-dose phase corresponded with the increases in hemoglobin observed across the daprodustat doses studied, which is similar to findings reported with other HIF-PHIs \[[@sfy014-B10], [@sfy014-B26]\]. The decrease in ferritin and TSAT and increase in TIBC are consistent with iron utilization due to increased erythropoiesis, and the decreased hepcidin could be an effect of the resultant decreased iron availability. The continued suppression of hepcidin and ferritin observed for the remainder of the trial in participants on daprodustat may reflect iron stores that remained lower than baseline with daprodustat \[[@sfy014-B27]\]. Although no difference in IV iron administration between treatment groups was observed, the interpretation of data is confounded since many participants continued IV iron despite exceeding the prespecified iron protocol stopping thresholds, and the study duration may have been insufficient to deplete iron stores to the point of elucidating a difference between treatments. Further work remains to understand the effects of daprodustat on iron metabolism and the resultant effects on IV iron requirements; these are being tested in a current Phase 3 trial (NCT03029208).

Treatment with daprodustat for up to 24 weeks demonstrated an AE profile consistent with the complex medical histories and cardiovascular comorbidities typical of this patient population. MACEs occurred more frequently in the daprodustat group, but these events were underpowered and not adjudicated, so definitive conclusions cannot be made. A long-term cardiovascular outcome study is ongoing to conclusively assess these associations. No emerging safety concerns based on the collective safety data, nor safety signals for any preidentified AE of interest, were identified for daprodustat.

An imbalance was also reported for the number of participants with a \>20 mmHg increase from baseline in estimated sPAP for the daprodustat group relative to controls, despite mean absolute changes from baseline in estimated sPAP being similar for both groups. This finding was not dose related. Changes in fluid status could not be ruled out as a confounder, given that the timing of echocardiograms (ECHOs) relative to dialysis day was inconsistent both within a given participant and between participants in the daprodustat and control groups. In a 24-week study in participants with CKD, who are less prone to fluid shifts as compared with participants on HD, there was no difference in estimated sPAP elevations \>20 mmHg in those receiving daprodustat compared with controls \[[@sfy014-B31]\]. Additionally, dedicated preclinical data (GlaxoSmithKline, unpublished data) and a clinical study in healthy volunteers \[[@sfy014-B28]\] demonstrated no effect of daprodustat on peak right ventricular pressure or sPAP, respectively, even in the setting of a hypoxic challenge.

Treatment with daprodustat did not raise BP. Consistent with the known AEs of rhEPO \[[@sfy014-B29]\], the control group had an increase in systolic BP at Week 24. Interpretation of the collective BP data is complicated by a greater proportion of participants on daprodustat reporting AEs of hypertension and having an increase in the number of antihypertensive medications relative to control. These imbalances may be due to more careful monitoring of BP in the combined daprodustat group, given it is an investigational drug, and underreporting of events in the control arm, given the known AE of hypertension with rhEPO.

Limitations of this trial include an uneven randomization ratio (4.5:1) resulting in a relatively small control group (*n* = 39) and the open-label design from Week 4 onward. Additionally, the tight eligibility criteria limit the generalizability of the findings, and the degree of noncompletion and large number of secondary outcomes complicates interpretation of the results. The open-label design could potentially influence how AEs are reported by participants or recorded by study staff for an investigational medication as compared with the standard of care. For example, more AEs of hyperkalemia were reported in the daprodustat group than in the control group, despite the fact that more hyperkalemia events of potential clinical importance were reported in the control group. This kind of bias may also have been true for the excess reports of nausea with daprodustat compared with controls. Nausea is common in patients on dialysis \[[@sfy014-B30]\]. More AEs of nausea reported in the daprodustat group could have been influenced by daprodustat being an investigational medication or the oral route of daprodustat administration. Cardiovascular events were not formally adjudicated and the study was not powered for any formal assessment of cardiovascular events. Lastly, the timing of the ECHO assessment relative to HD was not standardized and specific data to determine fluid shifts and estimated dry weight were not collected.

Overall, these data demonstrate that daprodustat produced dose-dependent changes from baseline in hemoglobin over the first 4 weeks and, with the dose-adjustment rules applied in this trial, daprodustat effectively achieves and maintains hemoglobin target levels after switching from a stable dose of rhEPO. This efficacy was achieved while maintaining effective plasma EPO levels and an AE profile consistent with that of the patient population. These data support continued development of daprodustat to treat anemia of CKD in patients receiving dialysis, including an ongoing large-scale cardiovascular outcomes trial (ASCEND-D) in patients receiving maintenance dialysis who are switching from rhEPO and its analogs (NCT02879305) and a trial in patients who are initiating dialysis (NCT03029208) to assess the safety and efficacy of daprodustat.
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[^1]: AE, adverse event; CHr, reticulocyte hemoglobin content; CV, cardiovascular; EPO, erythropoietin; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; QD, once daily; RBC, red blood cell; SAE, severe adverse event; sPAP, systolic pulmonary artery pressure; TIBC, total iron-binding capacity; TSAT, transferrin saturation; VEGF, vascular endothelial growth factor.

[^2]: Intent-to-treat population.

[^3]: Safety population.

[^4]: Low rhEPO dose: \<100 IU/kg/week epoetin or \<0.5 μg/kg/week darbepoetin; high rhEPO dose: ≥100 IU/kg/week epoetin or ≥0.5 μg/kg/week darbepoetin.

[^5]: BMI, body mass index; CV, cardiovascular; ITT, intent-to-treat; IU, international unit; rhEPO, recombinant human erythropoietin; SD, standard deviation.

[^6]: Baseline is the last predose value.

[^7]: Measurements in the daprodustat group were done predose and postdose 6--15 h after dosing; measurement in the control group was performed ∼5--15 min after dosing with rhEPO.

[^8]: CFB, change from baseline; EPO, erythropoietin; ITT, intent-to-treat; IU, international units; rhEPO, recombinant human erythropoietin; VEGF, vascular endothelial growth factor.

[^9]: CFB, change from baseline; CI, confidence interval; TIBC, total iron-binding capacity; TSAT, transferrin saturation.

[^10]: Cardiovascular events, including MACEs, defined as MI, stroke or death, were collected but were not formally adjudicated.

[^11]: A MACE is defined as a first occurrence of all-cause mortality, a nonfatal MI or a nonfatal stroke.

[^12]: A MACE+ is defined as a first occurrence of a MACE or hospitalization due to heart failure.

[^13]: Includes all events.

[^14]: MACE, major adverse cardiovascular event; MI, myocardial infarction.

[^15]: Baseline is the last predose value.

[^16]: DBP, diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation.
